Your Team for Swiss Law – désormais à Genève

Close

Que voudriez-vous rechercher?

Recherche du site
Filtres de recherche

Chambers Europe (2019) - "Life Sciences"

"A client describes Christian Wyss as "practical and knowledgeable" and another adds that "working with him is very easy and his responses are always on time." He acts for clients from the life sciences sector on financing and transactional matters, and assisted JSR Corporation with the Swiss aspects of its acquisition of Selexis. Wyss also advises on regulatory matters, such as research agreements and clinical trials."

Legal 500 (EMEA 2019) - "Healthcare and Life Sciences" - Tier 1

"VISCHER is renowned for its expertise in corporate, commercial, transactional, regulatory and patent-related healthcare and biotech matters. Matthias Staehelin assisted Medartis with its initial public offering on the SIX Swiss Exchange, while Stefan Kohler acted for Novo Nordisk Pharma in its appeal against a pricing decision made by the Swiss Federal Office of Public Health concerning the client's type-two diabetes product. Christian Wyss advised Lundbeck on its €905m acquisition of Prexton Therapeutics."

Legal 500 (EMEA 2019) - "Intellectual Property"

"The intellectual property department at VISCHER covers protective, strategic, transactional and contentious matters in relation to patents, copyright, designs and trade marks. Christian Wyss assisted Balderton Capital with the IP due diligence in preparation for its investment into Sophia Genetics' $30m financing round, while team lead Stefan Kohler advises Philipp Morris on the agreements required for the technological development of reduced-risk tobacco products. Rolf Der Maur, who combines intellectual property law with IT expertise, is another name to note."

Legal 500 (EMEA 2019) - "Leading Firms: German-Speaking Switzerland"

"VISCHER has core strength in the healthcare, TMT and transport sectors and notable public law expertise, while also fielding strong capital markets, M&A, competition and litigation departments. Key partners include Stefan Kohler, Rolf Auf der Maur, Stefan Rechsteiner, Benedict Christ and Christian Oetiker. Michael Waldner and Christian Wyss are other names to note."

Legal 500 (EMEA 2019) - "TMT" - Tier 1

"VISCHER's TMT practice has experience of sector-relevant convergence issues, regulatory requirements, online services licensing, outsourcing and transfer agreements. Rolf Auf der Maur successfully represented Swisscom as defendant in the first Swiss ISP-blocking matter brought by film rights holders, while Basel-based Christian Wyss assists Sympany with the review, drafting and negotiation of various different IT agreements with suppliers and outsourcing providers. Netflix, Quadrant and Additiv also feature in the client list."

Chambers Europe (2018) - "Life Sciences"

"Christian Wyss enters the rankings for the first time on the back of strong client support. One client enthuses that he is 'responsive, knowledgeable, considerate and intelligent.' Another source notes that he is 'careful in listening to the needs of the customer' and is a 'clear communicator.' His work includes assisting T3 Pharmaceuticals with various financing and licence agreements. He has further capabilities advising on acquisitions and collaborative agreements within the life sciences sector."

Legal 500 (EMEA 2018) - "Healthcare and life sciences" - Tier 1

"Vischer provides transactional, financing, capital markets, product launch and regulatory advice to health and life sciences industry clients and further represents them in contentious matters. The practice assisted JSR Corporation with its acquisition of Selexis and advised Axovant Sciences on its debt financing agreement with Hercules Capital. Stefan Kohler jointly heads the practice with Matthias Staehelin; Christian Wyss is another name to note."

Legal 500 (EMEA 2016) - "Healthcare and Life Sciences" - 1st tier

"Vischer has an ‘excellent’ regulatory practice, including compliance and administrative procedures, remarkable IP capabilities and a niche in acting for emerging biotech companies, where it advised GlycoVaxyn and Redvax on their sales to GlaxoSmithKline and Pfizer, respectively. Other clients include AstraZeneca, Novartis, Mattern Pharmaceuticals and IVF Zentren Prof. Zech. Stefan Kohler has ‘very broad knowledge’, including regulatory and IP matters, and is recommended along with Matthias Staehelin and newly promoted partner Christian Wyss."

Legal 500 (EMEA 2017) - "TMT"

"Vischer’s ‘highly skilled’ team assisted insurer Sympany with negotiating IT contracts and has been advising Ring Central on data protection and telecoms regulatory matters. Other clients include 3 Plus, Netflix and Swisscom. Rolf Auf der Maur and Christian Wyss are recommended."

You are currently offline. Some pages or content may fail to load.